Health Care Information and Resources

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Background Rimonabant (Acomplia, Zimulti), a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity–Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. Methods We randomly assigned [...]

Continue reading...